by Press Release on (#5AEEZ)
By NewsDesk @bactiman63 Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing viral and bacterial vaccines, today announced the results of a clinical study with an experimental vaccine against Shigella, intestinal bacteria that cause severe diarrhea and dysentery. Data were published in the prestigious journal The Lancet Infectious […]The post Shigella experimental vaccine: Intravacc publishes positive phase I data appeared first on Outbreak News Today.